Literature DB >> 22710711

TGF-β stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer.

M K Wendt1, B J Schiemann, J G Parvani, Y-H Lee, Y Kang, W P Schiemann.   

Abstract

Epithelial-mesenchymal transition (EMT) programs are essential in promoting breast cancer invasion, systemic dissemination and in arousing proliferative programs in breast cancer micrometastases, a reaction that is partially dependent on focal adhesion kinase (FAK). Many functions of FAK are shared by its homolog, protein tyrosine kinase 2 (Pyk2), raising the question as to whether Pyk2 also participates in driving the metastatic outgrowth of disseminated breast cancer cells. In addressing this question, we observed Pyk2 expression to be (i) significantly upregulated in recurrent human breast cancers; (ii) differentially expressed across clonal isolates of human MDA-MB-231 breast cancer cells in a manner predictive for metastatic outgrowth, but not for invasiveness; and (iii) dramatically elevated in ex vivo cultures of breast cancer cells isolated from metastatic lesions as compared with cells that produced the primary tumor. We further show that metastatic human and murine breast cancer cells robustly upregulate their expression of Pyk2 during EMT programs stimulated by transforming growth factor-β (TGF-β). Genetic and pharmacological inhibition of Pyk2 demonstrated that the activity of this protein tyrosine kinase was dispensable for the ability of breast cancer cells to undergo invasion in response to TGF-β, and to form orthotopic mammary tumors in mice. In stark contrast, Pyk2-deficiency prevented TGF-β from stimulating the growth of breast cancer cells in 3D-organotypic cultures that recapitulated pulmonary microenvironments, as well as inhibited the metastatic outgrowth of disseminated breast cancer cells in the lungs of mice. Mechanistically, Pyk2 expression was inversely related to that of E-cadherin, such that elevated Pyk2 levels stabilized β1 integrin expression necessary to initiate the metastatic outgrowth of breast cancer cells. Thus, we have delineated novel functions for Pyk2 in mediating distinct elements of the EMT program and metastatic cascade regulated by TGF-β, particularly the initiation of secondary tumor outgrowth by disseminated cells.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22710711      PMCID: PMC3721373          DOI: 10.1038/onc.2012.230

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  54 in total

1.  Different modes and qualities of tyrosine phosphorylation of Fak and Pyk2 during epithelial-mesenchymal transdifferentiation and cell migration: analysis of specific phosphorylation events using site-directed antibodies.

Authors:  K Nakamura; H Yano; E Schaefer; H Sabe
Journal:  Oncogene       Date:  2001-05-10       Impact factor: 9.867

2.  Pyk2 regulates multiple signaling events crucial for macrophage morphology and migration.

Authors:  M Okigaki; C Davis; M Falasca; S Harroch; D P Felsenfeld; M P Sheetz; J Schlessinger
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

3.  RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer cell invasion.

Authors:  S Zrihan-Licht; Y Fu; J Settleman; K Schinkmann; L Shaw; I Keydar; S Avraham; H Avraham
Journal:  Oncogene       Date:  2000-03-02       Impact factor: 9.867

4.  Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma.

Authors:  P L Judson; X He; W G Cance; L Van Le
Journal:  Cancer       Date:  1999-10-15       Impact factor: 6.860

5.  Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton.

Authors:  Dalit Barkan; Hynda Kleinman; Justin L Simmons; Holly Asmussen; Anil K Kamaraju; Mark J Hoenorhoff; Zi-yao Liu; Sylvain V Costes; Edward H Cho; Stephen Lockett; Chand Khanna; Ann F Chambers; Jeffrey E Green
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

6.  A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer.

Authors:  Pierre Farmer; Hervé Bonnefoi; Pascale Anderle; David Cameron; Pratyaksha Wirapati; Pratyakasha Wirapati; Véronique Becette; Sylvie André; Martine Piccart; Mario Campone; Etienne Brain; Gaëtan Macgrogan; Thierry Petit; Jacek Jassem; Frédéric Bibeau; Emmanuel Blot; Jan Bogaerts; Michel Aguet; Jonas Bergh; Richard Iggo; Mauro Delorenzi
Journal:  Nat Med       Date:  2009-01-04       Impact factor: 53.440

7.  Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs.

Authors:  Tsukasa Shibue; Robert A Weinberg
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-05       Impact factor: 11.205

Review 8.  Comparative genomic analysis of the eight-membered ring cystine knot-containing bone morphogenetic protein antagonists.

Authors:  Orna Avsian-Kretchmer; Aaron J W Hsueh
Journal:  Mol Endocrinol       Date:  2003-10-02

9.  In vivo dual substrate bioluminescent imaging.

Authors:  Michael K Wendt; Joseph Molter; Christopher A Flask; William P Schiemann
Journal:  J Vis Exp       Date:  2011-10-11       Impact factor: 1.355

10.  Latent bone metastasis in breast cancer tied to Src-dependent survival signals.

Authors:  Xiang H-F Zhang; Qiongqing Wang; William Gerald; Clifford A Hudis; Larry Norton; Marcel Smid; John A Foekens; Joan Massagué
Journal:  Cancer Cell       Date:  2009-07-07       Impact factor: 31.743

View more
  37 in total

1.  Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway.

Authors:  Nikolas Balanis; Michael K Wendt; Barbara J Schiemann; Zhenghe Wang; William P Schiemann; Cathleen R Carlin
Journal:  J Biol Chem       Date:  2013-05-07       Impact factor: 5.157

2.  Silencing β3 Integrin by Targeted ECO/siRNA Nanoparticles Inhibits EMT and Metastasis of Triple-Negative Breast Cancer.

Authors:  Jenny G Parvani; Maneesh D Gujrati; Margaret A Mack; William P Schiemann; Zheng-Rong Lu
Journal:  Cancer Res       Date:  2015-04-09       Impact factor: 12.701

Review 3.  The impact of low-dose carcinogens and environmental disruptors on tissue invasion and metastasis.

Authors:  Josiah Ochieng; Gladys N Nangami; Olugbemiga Ogunkua; Isabelle R Miousse; Igor Koturbash; Valerie Odero-Marah; Lisa J McCawley; Pratima Nangia-Makker; Nuzhat Ahmed; Yunus Luqmani; Zhenbang Chen; Silvana Papagerakis; Gregory T Wolf; Chenfang Dong; Binhua P Zhou; Dustin G Brown; Anna Maria Colacci; Roslida A Hamid; Chiara Mondello; Jayadev Raju; Elizabeth P Ryan; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Hosni K Salem; Amedeo Amedei; Rabeah Al-Temaimi; Fahd Al-Mulla; William H Bisson; Sakina E Eltom
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

Review 4.  Recent Advances in Discovering the Role of CCL5 in Metastatic Breast Cancer.

Authors:  Ayesha Khalid; Joy Wolfram; Ilaria Ferrari; Chaofeng Mu; Junhua Mai; Zhizhou Yang; Yuliang Zhao; Mauro Ferrari; Xiaojing Ma; Haifa Shen
Journal:  Mini Rev Med Chem       Date:  2015       Impact factor: 3.862

5.  Trpm2 enhances physiological bioenergetics and protects against pathological oxidative cardiac injury: Role of Pyk2 phosphorylation.

Authors:  Barbara A Miller; JuFang Wang; Jianliang Song; Xue-Qian Zhang; Iwona Hirschler-Laszkiewicz; Santhanam Shanmughapriya; Dhanendra Tomar; Sudasan Rajan; Arthur M Feldman; Muniswamy Madesh; Shey-Shing Sheu; Joseph Y Cheung
Journal:  J Cell Physiol       Date:  2019-01-13       Impact factor: 6.384

Review 6.  Understanding the roles of FAK in cancer: inhibitors, genetic models, and new insights.

Authors:  Hyunho Yoon; Joshua P Dehart; James M Murphy; Ssang-Taek Steve Lim
Journal:  J Histochem Cytochem       Date:  2014-11-07       Impact factor: 2.479

Review 7.  The relevance of the TGF-β Paradox to EMT-MET programs.

Authors:  Chevaun D Morrison; Jenny G Parvani; William P Schiemann
Journal:  Cancer Lett       Date:  2013-03-05       Impact factor: 8.679

8.  Upregulated WAVE3 expression is essential for TGF-β-mediated EMT and metastasis of triple-negative breast cancer cells.

Authors:  Molly A Taylor; Gangarao Davuluri; Jenny G Parvani; Barbara J Schiemann; Michael K Wendt; Edward F Plow; William P Schiemann; Khalid Sossey-Alaoui
Journal:  Breast Cancer Res Treat       Date:  2013-11-07       Impact factor: 4.872

9.  Pharmacologic Inhibition of FGFR Modulates the Metastatic Immune Microenvironment and Promotes Response to Immune Checkpoint Blockade.

Authors:  Saeed S Akhand; Zian Liu; Stephen C Purdy; Ammara Abdullah; Hang Lin; Gregory M Cresswell; Timothy L Ratliff; Michael Wendt
Journal:  Cancer Immunol Res       Date:  2020-10-22       Impact factor: 11.151

10.  Pyk2 promotes tumor progression in multiple myeloma.

Authors:  Yu Zhang; Michele Moschetta; Daisy Huynh; Yu-Tzu Tai; Yong Zhang; Wenjing Zhang; Yuji Mishima; Jennifer E Ring; Winnie F Tam; Qunli Xu; Patricia Maiso; Michaela Reagan; Ilyas Sahin; Antonio Sacco; Salomon Manier; Yosra Aljawai; Siobhan Glavey; Nikhil C Munshi; Kenneth C Anderson; Jonathan Pachter; Aldo M Roccaro; Irene M Ghobrial
Journal:  Blood       Date:  2014-09-12       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.